Experience of switching to NovoEight: views of people with haemophilia

Abstract

Management of haemophilia A requires administration of factor VIII therapy which, for those with severe haemophilia A in the UK, is predominantly self-administered at home in a prophylactic regimen to prevent or minimise bleeding. The UK undertakes a national tendering process every three years to ensure access to current and new therapies at a cost-effective price, through contracting for large volumes from individual suppliers. This means that some products may no longer be available and that new products can enter the UK market at any tendering stage.

Keywords

• novoeight
• switching treatment
• haemophilia
• patient experience
• people with haemophilia – views